Among Taiwan’s non-small cell lung cancer cases, approximately 55 percent involve an EGFR mutation, with deletion of exon 19 and exon 21 the most common mutations, treatable with first to ...

The non-small cell lung cancer (NSCLC) drug osimertinib (Tagrisso) was associated with an increased risk of therapy-related ...

The FDA bestows a Breakthrough Therapy designation to AstraZeneca and Daiichi Sankyo's Dato-DXd for previously treated ...

So, exciting opportunities with EGFR and met ADCs [antibody drug conjugates] as well as EGFR and CD3 T-cell engagers in the ...

Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological disea ...

NICE has turned down Tagrisso in the past in previously-untreated, EGFR-positive NSCLC but has now given its blessing to that use of the drug, as well as for second-line treatment of patients with ...

Dizal announces positive pooled data of sunvozertinib in EGFR TKI-resistant NSCLC: Shanghai, China Friday, December 13, 2024, 18:00 Hrs [IST] Dizal, a biopharmaceutical company co ...

Developed alongside AstraZeneca, the breakthrough designation comes following early pooled results from two ongoing trials ...

AZ is beginning the launch of its cancer drug Tagrisso (osimertinib) in first line lung cancer, taking market share from older EGFR drugs such as its own Iressa (gefitinib). Tagrisso had ...

Precision medicine is an innovative approach that tailors treatment to the unique genetic and molecular characteristics of a ...

The FDA has granted Breakthrough Therapy Designation to datopotamab deruxtecan (Dato-DXd) for advanced EGFR-mutated non-small cell lung cancer.